Psychedelic Insights | Tim Moore (CEO of HAVN Life) on the Acquisition of Spore Life Sciences

We interviewed Tim Moore, CEO of HAVN Life Sciences (CSE: HAVN) (OTC: HAVLF) regarding his firm’s recent acquisition of Spore Life Sciences.

Tim shared the strategy behind the acquisition and the resulting synergies; new opportunities and products within their distribution network. He also added colour to the functional mushroom competitive landscape and described the rapid growth of the market.

This is a lucrative acquisition for HAVN Life, as the agreement meets many of their objectives at once including acquiring a revenue generating business, market expansion and a short pathway to profitability in the near future. Read our full analysis here.

0 0 votes
Article Rating

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Notify of
Inline Feedbacks
View all comments